Skip to main

Deniz Peker, MD

Deniz Peker, MD

Background

Deniz Peker, MD, is Associate Professor in the Department of Pathology & Laboratory Medicine at Emory University School. Dr. Peker is board certified in hematopathology.

Dr. Peker received her Medical Degree from Erciyes University in Kayseri, Turkey. She completed her pathology residency at Istanbul University in Turkey, and at Mount Sinai Medical Center in Miami, Florida. She completed her hematopathology residency at Moffitt Cancer Center in Tampa, Florida.

Dr. Peker's research interest is in the biology and microenvironment in hematologic malignancies including leukemia, lymphoma and myeloma.

PubMed
Google Scholar

Titles & Roles

  • Professor, Department of Pathology and Laboratory Medicine
    Emory University School of Medicine

Education & Training

Education

  • Residency, Pathology-Hematology, 2012
    Moffitt Cancer Center
  • Fellowship, MD, Pathology, 2012
    University of South Florida College of Medicine
  • Internship, Anatomic Pathology & Clinical Pathology, 2010
    Mount Sinai Medical Center
  • Residency, Pathology, 2006
    Istanbul University Cerrahpasa Medical Faculty
  • Externship program, 2006
    Mount Sinai Medical Center
  • Externship program, 2003
    Nottingham University Hospitals NHS Trust
  • Medical Education, 2002
    Erciyes University

Board Certifications

  • Hematopathology
    American Board of Pathology, 2012
  • Anatomic and Clinical Pathology
    American Board of Pathology, 2011

Research

Publications

Title/Journal Authors Publication Date

Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

 D Rivera, W Cui, J Gao, D Peker, QY Zhang, R Dewar, L Qiu, S Konoplev, Z Hu, K Sasaki, AY Hu, S E, M Liu, H Fang, W Wang, G Tang, JF Apperley, A Hochhaus, JE Cortes, JD Khoury, LJ Medeiros, E Jabbour, S Hu 02/01/2024

Genetics and pathologic landscape of lineage switch of acute leukemia during therapy.

Blood cancer journal

 T Zhou, CV Curry, M Khanlari, M Shi, W Cui, D Peker, W Chen, E Wang, J Gao, Q Shen, W Xie, FZ Jelloul, RL King, J Yuan, X Wang, C Zhao, IE Obiorah, EL Courville, E Nomura, S Cherian, ML Xu, WR Burack, HX Liu, EJ Jabbour, K Takahashi, W Wang, SA Wang, JD Khoury, LJ Medeiros, S Hu 01/25/2024

Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder.

Current oncology reports

 M Lee, A Abousaud, RA Harkins, E Marin, D Balasubramani, MC Churnetski, D Peker, A Singh, JL Koff 08/01/2023

T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.

American journal of clinical pathology

 Z Hu, LJ Medeiros, M Xu, J Yuan, D Peker, L Shao, Z Tang, B Mai, B Thakral, A Rios, S Hu, W Wang 04/04/2023

Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.

Laboratory medicine

 OC Puglianini, D Peker, L Zhang, N Papadantonakis 01/05/2023

Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.

Archives of pathology & laboratory medicine

 AA Gru, MS Lim, A Dogan, SM Horwitz, J Delabie, K Fu, D Peker, VVB Reddy, ML Xu, K Vij, GW Slack, RN Miranda, D Jagadeesh, JM Lisano, ED Hsi, E Torlakovic 01/01/2023

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.

Blood

 P Li, S Brown, M Williams, T White, W Xie, W Cui, D Peker, L Lei, CA Kunder, HY Wang, SS Murray, J Vagher, T Kovacsovics, JL Patel 08/18/2022

AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome.

Leukemia

 P Li, T White, W Xie, W Cui, D Peker, G Zeng, HY Wang, J Vagher, S Brown, M Williams, T Kovacsovics, JL Patel 03/01/2022

The need for new test verification and regulatory support for innovative diagnostics.

Nature biotechnology

 JD Roback, EA Tyburski, D Alter, S Asakrah, A Chahroudi, A Esper, S Farmer, J Figueroa, J K Frediani, M D Gonzalez, D S Gottfried, J Guarner, N A Gupta, S S Heilman, C E Hill, R Jerris, R R Kempker, J Ingersoll, JM Levy, M Mavigner, C S Moreno, C R Morris, E J Nehl, A S Neish, D Peker, N Saakadze, PA Rebolledo, C A Rostad, N Schoof, A Suessmith, J Sullivan, YFW Wang, A Wood, MB Vos, O Brand, GS Martin, WA Lam 09/01/2021

EBV Positive Mucocutaneous Ulcer (EBVMCU): Single Center Series of Three Cases and Review of Literature.

Annals of clinical and laboratory science

 F Fei, V Reddy, D Peker, C Patel, S Al Diffalha 01/01/2021

Clinicopathologic and Molecular Analysis of Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma: A Case Report and Review of Literature.

Turk patoloji dergisi

 B Morales-Vargas, K Deeb, D Peker 01/01/2021

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.